Characterization of a survival pathway controlled by FGFR4 in alveolar Rhabdomyosarcoma

被引：0
|
作者：
Wachtel, Marco
Schafer, Beat
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-3418
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3418
引用
收藏
页数：3
相关论文
共 50 条
  • [21] THE ROLE OF FGFR4 IN NEUROBLASTOMA
    Whittle, Sarah
    Du, Melissa
    Zhang, Linna
    Woodfield, Sarah
    Scheurer, Michael
    Okcu, Fatih
    Zage, Peter
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S97 - S98
  • [22] FGFR4 specific chimeric antigen receptor (CAR) T cell therapy against rhabdomyosarcoma
    Shivaprasad, Nityashree
    Yohe, Marielle
    Xiong, Ying
    Wu, Darong
    Azorsa, Peter
    Cheuck, Adam
    Chung, Joon-Yong
    Zhu, Zhongyu
    Dimitrov, Dimiter
    Hewitt, Stephen
    Dropulic, Boro
    Schneider, Dina
    Orentas, Rimas
    Khan, Javed
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [23] Developing FGFR4 Chimeric Antigen Receptor CAR T Cell Therapy Against Rhabdomyosarcoma
    Shivaprasad, Nityashree
    Xiong, Ying
    Yohe, Marielle
    Schneider, Dina
    Shern, Jack
    Baskar, Sivasubramanian
    Dimitrov, Dimiter
    Sorenson, Paul
    Orentas, Rimas
    Khan, Javed
    MOLECULAR THERAPY, 2016, 24 : S257 - S258
  • [24] Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma
    Tian, Meijie
    Wei, Jun S.
    Shivaprasad, Nityashree
    Highfill, Steven L.
    Gryder, Berkley E.
    Milewski, David
    Gryder, Berkley
    Brown, G. Tom
    Moses, Larry
    Song, Hannah
    Wu, Jerry T.
    Azorsa, Peter
    Kumar, Jeetendra
    Schneider, Dina
    Chou, Hsien-Chao
    Song, Young K.
    Rahmy, Abdelrahman
    Masih, Katherine E.
    Kim, Yong Yean
    Belyea, Brian
    Linardic, Corinne M.
    Dropulic, Boro
    Sullivan, Peter M.
    Sorensen, Poul H.
    Dimitrov, Dimiter S.
    Maris, John M.
    Mackall, Crystal L.
    Orentas, Rimas J.
    Cheuk, Adam T.
    Khan, Javed
    CELL REPORTS MEDICINE, 2023, 4 (10390)
  • [25] Molecular mechanisms of Guadecita bine induced FGFR4 down regulation in alveolar rhabdomyosarcomas
    Darvishi, Emad
    Slemmons, Katherine
    Wan, Zesheng
    Mitra, Sheetal
    Hou, Xiaogang
    Parmentier, Jean Hugues
    Loh, Yong-Hwee Eddie
    Helman, Lee J.
    NEOPLASIA, 2020, 22 (07): : 274 - 282
  • [26] RNAi screening identifies FGFR4 as a modulator of growth and survival in Ewing sarcoma
    Azorsa, David O.
    Gonzales, Irma M.
    Arora, Shilpi
    Hagelstrom, R. Tanner
    Little, Tanya H.
    Arceci, Robert J.
    Mousses, Spyro
    CANCER RESEARCH, 2014, 74 (19)
  • [27] Discovery and characterization of a novel FGFR4 Inhibitor for the treatment of hepatocellular carcinoma
    Chen, Zhui
    CANCER RESEARCH, 2018, 78 (13)
  • [28] Targeting PI3K/mTOR in mouse rhabdomyosarcoma models driven by FGFR4 activation
    McKinnon, Timothy
    Venier, Rosemarie
    Yohe, Marielle
    Gryder, Berkley E.
    Dickson, Brendan
    Schleicher, Krista
    Davani, Dariush
    Wei, Winnie
    Guidos, Cynthia
    Gupta, Abha
    Khan, Javed
    Gladdy, Rebecca
    CLINICAL CANCER RESEARCH, 2018, 24 (02) : 58 - 58
  • [29] Fgfr4 is required for effective muscle regeneration in vivo -: Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway
    Zhao, P
    Caretti, G
    Mitchell, S
    McKeehan, WL
    Boskey, AL
    Pachman, LM
    Sartorelli, V
    Hoffman, EP
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (01) : 429 - 438
  • [30] EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma
    Shen, Bin
    Shi, Jue-Ping
    Zhu, Zhi-Xuan
    He, Zhi-Dong
    Liu, Shen-Yan
    Shi, Wan
    Zhang, Yong-Xian
    Ying, Hai-Yan
    Wang, Jie
    Xu, Rui-Feng
    Fang, Fei
    Chang, Harrison Xuesong
    Chen, Zhui
    Zhang, Nan-Nan
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12) : 1479 - 1492
12345